Basimglurant

Drug Profile

Basimglurant

Alternative Names: RG-7090; RO-4917523

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class Antidepressants; Fluorobenzenes; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Discontinued Fragile X syndrome

Most Recent Events

  • 17 Aug 2015 Phase-II development for treatment-resistant depression is ongoing in US, EU, Japan, Chile, Mexico, Russia and Taiwan
  • 01 Aug 2015 Roche completes a phase I trial for Major depressive disorder in USA (NCT02433093)
  • 10 Feb 2015 Discontinued - Phase-II for Fragile X syndrome (In adolescents, In adults) in USA, Argentina, Canada, Chile, France, Mexico, Peru, Spain, Sweden and United Kingdom (PO) before February 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top